InsidersTradesSigma
Follow the Karuna Therapeutics, Inc. share price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Karuna Therapeutics, Inc. has published 119 insider filings. The latest transaction was filed on 18 March 2024 (Disposition). Among the most active insiders: Brannan Stephen K.. Every trade is accessible without an account.
119
Insider Decl.
n/a
Thresholds
€3m
4 ops.
Buy Volume
€38m
18 ops.
Sell Volume
42Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 March 2024
Declarations119 total
10,342 shares@ US$330.0055.9% of flowCommon StockSEC:0001140361-24-013928:0
14,009 shares@ US$330.0098.1% of flowCommon StockSEC:0001140361-24-013923:0
990 shares@ US$330.0030.4% of flowCommon StockSEC:0001140361-24-013932:0
990 shares@ US$330.0018.3% of flowCommon StockSEC:0001140361-24-013931:0
13,977 shares@ US$330.0073.7% of flowCommon StockSEC:0001140361-24-013930:0
990 shares@ US$330.00100.0% of flowCommon StockSEC:0001140361-24-013924:0
990 shares@ US$330.0052.1% of flowCommon StockSEC:0001140361-24-013926:0
2,046 shares@ US$330.004.1% of flowCommon StockSEC:0001140361-24-013933:0
990 shares@ US$330.00100.0% of flowCommon StockSEC:0001140361-24-013934:0
32,500 shares@ US$330.0071.7% of flowCommon StockSEC:0001140361-24-013925:0
36,117 shares@ US$330.0083.4% of flowCommon StockSEC:0001140361-24-013922:0
990 shares@ US$330.00100.0% of flowCommon StockSEC:0001140361-24-013935:0
5,000 shares@ US$330.0058.2% of flowCommon StockSEC:0001140361-24-013927:0
2,500 shares@ US$5.450.1% of flowCommon StockSEC:0000950170-24-029406:0
47,378 shares@ US$315.1891.6% of flowCommon StockSEC:0000950170-24-024999:0
27,510 shares@ US$7.271.2% of flowCommon StockSEC:0000950170-24-020397:0
278 shares@ US$318.001.9% of flowCommon StockSEC:0000950170-24-015963:0
2,500 shares@ US$5.450.1% of flowCommon StockSEC:0000950170-24-013959:0
1,011 shares@ US$317.145.2% of flowCommon StockSEC:0000950170-24-013962:0
804 shares@ US$317.141.6% of flowCommon StockSEC:0000950170-24-013963:0
2,500 shares@ US$5.450.1% of flowCommon StockSEC:0000950170-24-003372:0
8,694 shares@ US$316.3044.1% of flowCommon StockSEC:0000950170-23-073877:0
3,828 shares@ US$316.3041.8% of flowCommon StockSEC:0000950170-23-073878:0
2,500 shares@ US$5.450.1% of flowCommon StockSEC:0000950170-23-069766:0
2,500 shares@ US$5.450.1% of flowCommon StockSEC:0000950170-23-063121:0
25 of 119 declarations
关于 Karuna Therapeutics, Inc.
Karuna Therapeutics, Inc.（股票代码 KRTX）是一家总部位于美国的生物制药公司，专注于神经科学和精神病学。该公司在美国纳斯达克上市，在 Bristol Myers Squibb 于 2024 年 3 月 18 日完成收购后，其作为独立上市公司停止运营。因此，Karuna 如今最好被理解为一家前上市公司，其主要遗产是开发针对精神和神经系统疾病的差异化疗法。其历史总部位于马萨诸塞州波士顿，地址是 99 High Street。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1771917/000114036124013927/xslF345X05/form4.xml?utm_source=openai)) Karuna 围绕一个针对中枢神经系统疾病的研究平台建立，特别强调毒蕈碱受体调节。其主要资产是 KarXT（xanomeline-trospium），这是一种口服的、同类首创或潜在同类首创的抗精神病药物，专为成人精神分裂症设计，并在阿尔茨海默病精神病和其他神经精神疾病方面进行了额外的开发工作。该公司的故事是一个专注于临床阶段创新者的故事，而不是一个多元化的制药集团：它旨在通过一个高度差异化的科学平台和少量高影响力项目创造价值。（[nasdaq.com](https://www.nasdaq.com/press-release/bristol-myers-squibb-strengthens-neuroscience-portfolio-with-acquisition-of-karuna?utm_source=openai)) 从竞争角度来看，Karuna 在精神病学和神经病学交叉领域占据了一个利基市场，间接与已有的抗精神病药物以及更广泛的行业对更有效、耐受性更好的治疗方法的探索竞争。其竞争优势在于 KarXT 的新颖机制以及解决精神分裂症及相关疾病中未满足需求的可能性。与此同时，Karuna 具有临床阶段生物技术公司的典型风险特征：严重依赖单一主要资产、二元监管里程碑以及没有大型商业特许经营权来缓冲挫折。（[nasdaq.com](https://www.nasdaq.com/press-release/bristol-myers-squibb-strengthens-neuroscience-portfolio-with-acquisition-of-karuna?utm_source=openai)) 从地理上看，Karuna 的业务主要以美国为中心，其研究和公司基地位于波士顿，其最初的商业/监管目标是通过 FDA 专注于美国市场。最近的一个重要里程碑是 2023 年 12 月 22 日宣布 Bristol Myers Squibb 将以每股 330.00 美元的现金收购 Karuna，这意味着股权价值约为 14.0 billion 美元。该交易于 2024 年 3 月 18 日完成，Karuna 成为 Bristol Myers Squibb 神经科学产品组合的一部分。对于国际投资者而言，这意味着 KRTX 现在主要是美国生物技术领域的一个历史参考点，而不是一家独立交易的运营公司。（[nasdaq.com](https://www.nasdaq.com/press-release/bristol-myers-squibb-strengthens-neuroscience-portfolio-with-acquisition-of-karuna?utm_source=openai))
